Latest News

  • Novel NGS-Based Assay Has Seemingly Limitless Virus Detection Potential

    Diagnostics World | Scientists at the Center for Infection and Immunity (CII) at Columbia University Mailman School of Public Health have created a next-generation sequencing (NGS) technology that employs oligonucleotides (oligos)—short single strands of synthetic DNA—as bait for relevant targets of detection.

    Feb 7, 2024
  • Protein Signatures Of Organ Aging Could Aid Disease Prevention Efforts

    Diagnostics World | Stanford Medicine investigators are leading the development of a test measuring organ-specific proteins in the blood as a simple and sensible way to estimate biological age. Among the potential applications are screening people for conditions such as heart failure and Alzheimer’s disease, personalizing the intervention they’re prescribed, and signaling sooner the efficacy of investigational drugs based on how well they rejuvenate certain organs.

    Feb 6, 2024
  • Oxford Nanopore Expands Respiratory Pilot Program, Imagine Pharma Launches Foundation, Collaborations for Rare Diseases, More

    Diagnostics World | Oxford Nanopore Technologies and Guy’s and St Thomas’ NHS Foundation Trust have collaborated and successfully completed a pilot program meant to deliver a respiratory metagenomics service with an integrated respiratory infection and biosecurity application; Imagine Pharma announced the formation of The Imagine Pharma Foundation, a private, not-for-profit charitable organization dedicated to advancing metabolic research to significantly impact the lives of those affected by diabetes, with a particular emphasis on serving veterans; DNAnexus and TMA Precision Health announced a collaboration to advance basic and translational research for patients who have a rare disease; more.

    Jan 31, 2024
  • Follow the Money: Cleveland Diagnostics Expands Development, Depression Treatment Implant Device, Major Liver Cirrhosis Study, More

    Diagnostics World | Cleveland Diagnostics intends to accelerate the company’s commercial and corporate development goals; Motif Neurotech has secured funding for the development of lead product, DOT microstimulator, to treat depression; Newcastle University, University of Edinburgh, and Boehringer Ingelheim will begin the most extensive clinical study into liver cirrhosis ever to better understand NASH cirrhosis and identifying translational biomarkers; more.

    Jan 30, 2024